ClinicalTrials.gg
Status unknownNCT04448379Updated Dec 28, 2020

Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung Cancer

A Phase 1 interventional study of JMT101 in Locally Advanced or Metastatic Non-Small Cell Lung Cancer, sponsored by Shanghai JMT-Bio Inc.. Status unknown at 13 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-12-28.

Sponsored by Shanghai JMT-Bio Inc. (part of CSPC Pharmaceutical Group Limited) · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jul 2020), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 17 studies in Carcinoma, Non-Small-Cell Lung by CSPC Pharmaceutical Group Limited — 11 open to participants now, 12 under way, 7 of them phase 3. Carcinoma, Non-Small-Cell Lung · CSPC Pharmaceutical Group Limited.

Planned enrollment
16th of 16
48 · median 365
Started
2020
the only one that year
Phase 1
2 of 17
none open now
Registered
3rd of 17
by date

Among the 17 studies in Carcinoma, Non-Small-Cell Lung by CSPC Pharmaceutical Group Limited, this one is the 16th largest by planned enrollment of the 16 interventional ones that give a count, is the only one that started in 2020, is one of 2 in phase 1, and was the 3rd registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

11 of the 17 studies in Carcinoma, Non-Small-Cell Lung by CSPC Pharmaceutical Group Limited are open now, in 1 country. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Where they have run

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Carcinoma, Non-Small-Cell Lung by CSPC Pharmaceutical Group Limited, or all of them as a file.
02

Study summary

This study is a Phase Ib, open label, multi-center study of to evaluate the safety and efficacy of JMT101 combined with EGFR-TKIs (Afatinib or Osimertinib) in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations.

Read the detailed description

The objective of the trial is to evaluate the safety and efficacy of JMT101 combined with EGFR-TKIs (afatinib or osimertinib) in patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations.

This study consists of two parts (Stage I and Stage II). Stage I was a dose escalation study, and Stage II was a dose expansion study.

03

Conditions studied

  • Locally Advanced or Metastatic Non-Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed, locally advanced or NSCLC, harboring an EGFR exon 20 insertion mutation. ( non-irradiable, non-operable);
  • No previous treatment or treatment failed NSCLC;
  • At least 1 according to 1.1;
  • score 0 or 1;

Exclusion criteria

Exclusion Criteria:

  • Previously treated with EGFR antibody;
  • Symptomatic ;
  • Interstitial pneumopathy;
  • Known to any ingredient of JMT101, afatinib, osimertinib or their ;
  • Receiving an product in another clinical study within 4 weeks;
  • History of serious systemic diseases;
  • History of serious diseases;
  • Pregnancy or lactating women.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    Dose Escalation Cohort

    Two dose levels of JMT101 combined with afatinib or osimertinib will be tested according to the "3 + 3" dose-escalation design. The dose-limiting toxicity (DLT) will be assessed from the first administration to the end of the first cycle (28 days).

    Drug: JMT101

  • Experimental
    Dose Expansion Cohort

    Once the effective dose has been determined, an expansion cohort will be opened to evaluate the efficacy and safety of the selected dose.

    Drug: JMT101

Interventions

  • DrugJMT101

    IV infusion Q2W for 4 weeks (28-day cycles)

    Also known as: Afatinib or Osimertinib

This study also gives Osimertinib. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events (defined by the Common Terminology Criteria for Adverse Events version 5.0 (CTCAE V5.0)).

    Time frame: From enrollment until 30 days after the last dose

Secondary outcomes

  1. Objective Response Rate (ORR) Assessed by Blinded Independent Review Committee (IRC) per RECIST Version 1.1

    Time frame: From first dose to disease progression or end of study, an average of 1 year

  2. Disease control rate (DCR).

    Time frame: From first dose to disease progression or end of study, an average of 1 year

  3. Progression free survival (PFS).

    Time frame: From first dose to disease progression or end of study, an average of 1 year

  4. Overall survival (OS).

    Time frame: From first dose to death or end of study, an average of 1 year

  5. Area under the concentration curve from time 0 to the concentration at last time point (AUC0-last) of JMT101.

    Time frame: From enrollment until 30 days after the last dose

  6. Maximum measured plasma concentration (Cmax) of JMT101.

    Time frame: From enrollment until 30 days after the last dose

  7. Time to maximum plasma concentration (Tmax) of JMT101.

    Time frame: From enrollment until 30 days after the last dose

  8. Half-life (T1/2) of JMT101.

    Time frame: From enrollment until 30 days after the last dose

  9. Immunogenicity profile of JMT101.

    Blood samples will be collected from subjects post treatment for assessment to detect the presence of anti-drug antibodies and neutralizing antibodies.

    Time frame: From enrollment until 30 days after the last dose

  10. Potential biomarkers detected in plasma circulating tumor DNA.

    Time frame: From enrollment up to disease progression, an average of 1 year

07

Study locations

13 of 13 sites recruiting
  • Sun Yat-sen University Cancer Center
    Guangzhou, Guangdong 510060, China
    Recruiting
  • The Fourth Hospital of Hebei Medical University
    Shijiazhuang, Hebei 050000, China
    Recruiting
  • Chinese Pla General Hospital
    Beijing, China
    Recruiting
    • Yi Hu · Contact
  • Hunan Cancer Hospital
    Changsha, China
    Recruiting
    • Lin Wu · Contact
  • West China Hospital of Sichuan University
    Chengdu, China
    Recruiting
    • Feng Luo · Contact
  • Fujian Cancer Hospital
    Fuzhou, China
    Recruiting
    • Wu Zhuang · Contact
  • Zhejiang Cancer Hospital
    Hangzhou, China
    Recruiting
    • Yiping Zhang · Contact
  • Jiangsu Province Hospital of Chinese Medicine
    Nanjing, China
    Recruiting
    • Qian Wang · Contact
  • Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School
    Nanjing, China
    Recruiting
    • Liyun Miao · Contact
  • Shanghai Chest Hospital, Shanghai Jiaotong University
    Shanghai, China
    Recruiting
    • Baohui Han · Contact
  • Shanxi Bethune Hospital (Shanxi Academy of Medical Sciences)
    Taiyuan, China
    Recruiting
    • Junping Zhang · Contact
  • Shanxi Province Cancer Hospital
    Taiyuan, China
    Recruiting
    • Wei Guo · Contact
  • Union Hospital, affiliated with TongJi Medical College, HuaZhong University of Science and Technology
    Wuhan, China
    Recruiting
    • Xiaorong Dong · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2020 (actual). Primary completion is estimated for Dec 2021, 18 months after the start.

Of 473 industry-sponsored phase 1 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's planned 18 months is below that.

Counting every sponsor, half of 699 studies reached it within 50 months; a quarter within 31 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2020
First posted
Jun 25, 2020
StartActual
Jun 29, 2020
Primary completionEst.
Dec 31, 2021
CompletionEst.
Jun 30, 2022
Last update
Dec 28, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 28, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04448379
Responsible party
Sponsor
First posted
Jun 25, 2020
Start date
Jun 29, 2020
Primary completion
Dec 31, 2021 (estimated)
Completion
Jun 30, 2022 (estimated)
Last update
Dec 28, 2020

Study contacts

Xiugao Yang
Contact
yangxiugao@mail.ecspc.com
8021-60677906
Rong Hu
Contact
hurong@mail.ecspc.com
8021-60673935

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Becotatug

Start the discussion